BL 1230

Drug Profile

BL 1230

Alternative Names: BL-1230

Latest Information Update: 14 Dec 2016

Price : $50

At a glance

  • Originator Hebrew University of Jerusalem
  • Developer BioLineRx; Novartis
  • Class
  • Mechanism of Action Cannabinoid receptor CB2 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Dry eyes

Most Recent Events

  • 21 Nov 2016 BioLineRx has patents pending for BL 1230 in the US, Europe and other countries (BioLineRx website, December 2016)
  • 21 Nov 2016 Preclinical trials in Dry eyes in Israel (Topical)
  • 21 Nov 2016 BioLineRx in-licenses BL 1230 from Yissum Research Development Company
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top